3,444 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by MJT & Associates Financial Advisory Group Inc.

Key Points

• MJT & Associates Financial Advisory Group Inc. has acquired 3,444 shares of Johnson & Johnson valued at approximately $571,000, making it the firm's 21st largest position.
• Several institutional investors, including New Republic Capital LLC and KFA Private Wealth Group LLC, have increased their stakes in Johnson & Johnson, reflecting growing investor interest.
• Johnson & Johnson recently reported quarterly earnings of $2.77 EPS, exceeding estimates, with a revenue of $23.74 billion, indicating a revenue growth of 5.8% compared to the previous year.

MJT & Associates Financial Advisory Group Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,444 shares of the company's stock, valued at approximately $571,000. Johnson & Johnson accounts for 0.5% of MJT & Associates Financial Advisory Group Inc.'s portfolio, making the stock its 21st largest position.

Several other large investors have also recently added to or reduced their stakes in JNJ. Atlantic Family Wealth LLC lifted its holdings in Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after buying an additional 67 shares during the period. MBA Advisors LLC increased its stake in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after purchasing an additional 68 shares in the last quarter. Sovereign Financial Group Inc. increased its stake in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after purchasing an additional 69 shares in the last quarter. Nabity Jensen Investment Management Inc increased its stake in Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after purchasing an additional 69 shares in the last quarter. Finally, Jackson Grant Investment Advisers Inc. increased its stake in Johnson & Johnson by 0.5% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 12,970 shares of the company's stock valued at $2,151,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 1.2%

Johnson & Johnson stock traded down $1.99 during mid-day trading on Thursday, reaching $165.27. The company's stock had a trading volume of 4,547,807 shares, compared to its average volume of 9,028,843. The company has a market capitalization of $398.02 billion, a price-to-earnings ratio of 17.69, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The business's 50 day simple moving average is $156.93 and its 200 day simple moving average is $156.30. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the company posted $2.82 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.15%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on JNJ shares. Morgan Stanley upped their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Bank of America upped their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, UBS Group increased their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.